Advertisement
Screener

Korro Bio, Inc. (KRRO) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

Korro Bio, Inc. Increase (Decrease) in Accrued Liabilities

Korro Bio, Inc. (KRRO) reported Increase (Decrease) in Accrued Liabilities of -$2.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06

  • Korro Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$2.32M, a 215.73% decline year-over-year.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$205.00K.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $1.75M, a 119.85% increase year-over-year.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $189.00K.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $1.43M.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$3.97M, a 412.52% decline from fiscal 2023.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.27M.
  • Korro Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$39.00K.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accrued Liabilities 12 monthIncrease (Decrease) in Accrued Liabilities 12 month as first filed
2026-06-30-$2.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$2.52M
10-Q · filed 2026-08-06
-$773.00K
derived: sum of 3 quarters · filed 2026-08-06
-$584.00K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$205.00K
10-Q · filed 2026-05-07
$1.54M
derived: sum of 2 quarters · filed 2026-05-07
$1.73M
derived: sum of 3 quarters · filed 2026-05-07
$3.74M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$1.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$1.94M
derived: sum of 2 quarters · filed 2026-03-12
$3.94M
derived: sum of 3 quarters · filed 2026-08-06
$1.43M
10-K · filed 2026-03-12
2025-09-30$189.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$2.19M
derived: sum of 2 quarters · filed 2026-08-06
-$319.00K
10-Q · filed 2025-11-12
$477.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$2.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$508.00K
10-Q · filed 2026-08-06
$288.00K
derived: sum of 3 quarters · filed 2026-08-06
-$428.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$2.51M
10-Q · filed 2026-05-07
-$1.72M
derived: sum of 2 quarters · filed 2026-05-07
-$2.43M
derived: sum of 3 quarters · filed 2026-05-07
-$1.43M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$796.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$80.00K
derived: sum of 2 quarters · filed 2026-03-12
$1.08M
derived: sum of 3 quarters · filed 2026-03-12
-$3.97M
10-K · filed 2026-03-12
2024-09-30-$716.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$283.00K
derived: sum of 2 quarters · filed 2025-11-12
-$4.76M
10-Q · filed 2025-11-12
-$5.22M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$999.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$4.05M
10-Q · filed 2025-08-12
-$4.51M
derived: sum of 3 quarters · filed 2025-08-12
-$2.56M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$5.05M
10-Q · filed 2025-05-07
-$5.51M
derived: sum of 2 quarters · filed 2025-05-07
-$3.56M
derived: sum of 3 quarters · filed 2025-05-07
-$2.66M
derived: sum of 4 quarters · filed 2025-05-07
2023-12-31-$460.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18
$1.49M
derived: sum of 2 quarters · filed 2025-03-18
$2.39M
derived: sum of 3 quarters · filed 2025-03-18
$1.27M
10-K · filed 2025-03-18
2023-09-30$1.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$2.85M
derived: sum of 2 quarters · filed 2024-11-12
$1.73M
10-Q · filed 2024-11-12
$2.19M
10-Q · filed 2023-11-02
$2.09M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$896.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$221.00K
10-Q · filed 2024-08-13
-$782.00K
10-Q · filed 2023-08-10
$136.00K
derived: sum of 3 quarters · filed 2024-08-13
$361.00K
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$1.12M
10-Q · filed 2024-05-14
-$413.00K
10-Q · filed 2023-05-12
-$760.00K
derived: sum of 2 quarters · filed 2024-05-14
-$535.00K
derived: sum of 3 quarters · filed 2024-05-14
$196.00K
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$357.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26
$582.00K
derived: sum of 2 quarters · filed 2024-03-26
$1.31M
derived: sum of 3 quarters · filed 2024-03-26
-$39.00K
10-K · filed 2024-03-26
-$208.00K
10-K · filed 2023-03-10
2022-09-30$225.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$956.00K
derived: sum of 2 quarters · filed 2023-11-02
-$396.00K
10-Q · filed 2023-11-02
$408.00K
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30$731.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$621.00K
10-Q · filed 2023-08-10
$183.00K
derived: sum of 3 quarters · filed 2023-08-10
$1.75M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$1.35M
10-Q · filed 2023-05-12
-$548.00K
derived: sum of 2 quarters · filed 2023-05-12
$1.02M
derived: sum of 3 quarters · filed 2023-05-12
$2.28M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$804.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10
$2.37M
derived: sum of 2 quarters · filed 2023-03-10
$3.63M
derived: sum of 3 quarters · filed 2023-03-10
-$398.00K
10-K · filed 2023-03-10
-$794.00K
10-K · filed 2022-03-15
2021-09-30$1.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$2.83M
derived: sum of 2 quarters · filed 2022-11-08
-$1.20M
10-Q · filed 2022-11-08
$1.01M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$1.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$2.77M
10-Q · filed 2022-08-09
-$558.00K
derived: sum of 3 quarters · filed 2022-08-09
$433.00K
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$4.03M
10-Q · filed 2022-05-04
-$1.82M
derived: sum of 2 quarters · filed 2022-05-04
-$828.00K
derived: sum of 3 quarters · filed 2022-05-04
$369.00K
derived: sum of 4 quarters · filed 2022-05-04
2020-12-31$2.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$3.21M
derived: sum of 2 quarters · filed 2022-03-15
$4.40M
derived: sum of 3 quarters · filed 2022-03-15
$3.08M
10-K · filed 2022-03-15
2020-09-30$991.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$2.19M
derived: sum of 2 quarters · filed 2021-11-15
$869.00K
10-Q · filed 2021-11-15
$892.00K
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$1.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$122.00K
10-Q · filed 2021-08-12
-$99.00K
derived: sum of 3 quarters · filed 2021-08-12
$625.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$1.32M
10-Q · filed 2021-05-13
-$1.30M
derived: sum of 2 quarters · filed 2021-05-13
-$572.00K
derived: sum of 3 quarters · filed 2021-05-13
$654.00K
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$23.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$747.00K
derived: sum of 2 quarters · filed 2021-03-29
$1.97M
derived: sum of 3 quarters · filed 2021-03-29
$1.49M
10-K · filed 2021-03-29
2019-09-30$724.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
$1.95M
derived: sum of 2 quarters · filed 2020-11-16
$1.47M
10-Q · filed 2020-11-16
2019-06-30$1.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
$743.00K
10-Q · filed 2020-08-12
2019-03-31-$483.00K
10-Q · filed 2020-05-14
2018-12-31$677.00K
10-K · filed 2020-03-26
2017-12-31$365.00K
10-K · filed 2020-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atrium Therapeutics, Inc. (RNA)United States$0.140B
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88